Confluence Investment Management LLC Sells 9,259 Shares of Charles River Laboratories International, Inc. $CRL

Confluence Investment Management LLC trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 10.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,373 shares of the medical research company’s stock after selling 9,259 shares during the quarter. Confluence Investment Management LLC’s holdings in Charles River Laboratories International were worth $24,301,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Continuum Advisory LLC acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at about $30,000. SHP Wealth Management bought a new position in shares of Charles River Laboratories International during the fourth quarter worth about $85,000. Eurizon Capital SGR S.p.A. acquired a new position in Charles River Laboratories International in the fourth quarter worth about $104,000. Trust Asset Management LLC bought a new stake in Charles River Laboratories International in the second quarter valued at about $129,000. Finally, Hilltop National Bank raised its stake in Charles River Laboratories International by 28.7% during the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock valued at $129,000 after buying an additional 127 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity

In other news, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James Foster sold 33,561 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $9,478,800. This represents a 51.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 90,990 shares of company stock valued at $25,731,388 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL traded down $7.06 during mid-day trading on Thursday, hitting $287.95. The stock had a trading volume of 226,961 shares, compared to its average volume of 925,277. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company has a 50 day simple moving average of $275.03 and a 200-day simple moving average of $216.10. The stock has a market capitalization of $13.75 billion, a price-to-earnings ratio of -59.34, a P/E/G ratio of 2.76 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $303.30.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on CRL shares. Morgan Stanley lifted their target price on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Mizuho raised their price objective on Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th. Jefferies Financial Group lifted their price objective on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the stock a “buy” rating in a report on Monday. Robert W. Baird raised their price target on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the stock an “outperform” rating in a research report on Friday, September 25th. Finally, CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Moderate Buy” and a consensus target price of $300.11.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.